SCHEMBL14938517

SCHEMBL14938517

Cc1nc(N2CCCC(F)(F)C2)ccc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.49
ALDH1A1 P00352 7/20 0.49
MAPK1 P28482 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.39
CYP1A2 P05177 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 1/20 0.36
EIF2AK4 Q9P2K8 1/20 0.36
TNNI3 P19429 1/20 0.36
TNNT2 P45379 1/20 0.36
TNNC1 P63316 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14938519 0.92 ALDH1A1 (0.45) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL2067936 0.87 MAPT (0.46) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL2068371 0.82 MAPT (0.65) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL2898709 0.82 MAPT (0.69) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL14938629 0.78 EIF2AK4 (0.39) EIF2AK4
SCHEMBL31703634 0.75 MAPT (0.47) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL29739299 0.74 MAPT (0.68) MAPTALDH1A1MAPK1POLBHPGD
SCHEMBL14938740 0.73 MAPT (0.46) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL2256829 0.73 MAPT (0.57) MAPTALDH1A1MAPK1TDP1POLB
SCHEMBL14938603 0.73 MAPT (0.46) MAPTALDH1A1MAPK1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776445-B1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2016-08-10 EP disclosed
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 US disclosed
EP-2776445-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB Pharma, S.A. (BE) 2014-09-17 EP disclosed
WO-2013068458-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 MAPT 2357/4885ALDH1A1 708/4885MAPK1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.